Meteb Al‐Foheidi

566 total citations
20 papers, 200 citations indexed

About

Meteb Al‐Foheidi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Meteb Al‐Foheidi has authored 20 papers receiving a total of 200 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Meteb Al‐Foheidi's work include HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (4 papers) and Breast Cancer Treatment Studies (4 papers). Meteb Al‐Foheidi is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (4 papers) and Breast Cancer Treatment Studies (4 papers). Meteb Al‐Foheidi collaborates with scholars based in Saudi Arabia, Egypt and Lebanon. Meteb Al‐Foheidi's co-authors include Ezzeldin M. Ibrahim, Mubarak Al‐Μansour, Ghieth A. Kazkaz, Turki Alfayea, Tagwa Omer, Mark F. McEntee, Tahir Yunus, William Rae, Ahmed Al‐Jedai and Ernest Ekpo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Meteb Al‐Foheidi

18 papers receiving 196 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Meteb Al‐Foheidi 109 54 38 32 30 20 200
Tobias Engler 84 0.8× 21 0.4× 32 0.8× 52 1.6× 29 1.0× 42 207
Akira Yabuno 79 0.7× 31 0.6× 51 1.3× 67 2.1× 19 0.6× 37 322
Joan Tymon‐Rosario 103 0.9× 24 0.4× 45 1.2× 34 1.1× 45 1.5× 34 294
Luca Seriau 83 0.8× 33 0.6× 37 1.0× 75 2.3× 15 0.5× 17 228
Britt B.M. Suelmann 95 0.9× 12 0.2× 44 1.2× 29 0.9× 30 1.0× 31 214
Hilary Stobart 71 0.7× 43 0.8× 28 0.7× 82 2.6× 21 0.7× 33 215
Amandeep Godara 86 0.8× 20 0.4× 17 0.4× 13 0.4× 26 0.9× 50 259
Caigang Xu 84 0.8× 84 1.6× 21 0.6× 50 1.6× 18 0.6× 39 241
Shu-Lian Wang 155 1.4× 52 1.0× 39 1.0× 106 3.3× 18 0.6× 6 230
Constanze Elfgen 76 0.7× 51 0.9× 48 1.3× 106 3.3× 26 0.9× 29 258

Countries citing papers authored by Meteb Al‐Foheidi

Since Specialization
Citations

This map shows the geographic impact of Meteb Al‐Foheidi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meteb Al‐Foheidi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meteb Al‐Foheidi more than expected).

Fields of papers citing papers by Meteb Al‐Foheidi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meteb Al‐Foheidi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meteb Al‐Foheidi. The network helps show where Meteb Al‐Foheidi may publish in the future.

Co-authorship network of co-authors of Meteb Al‐Foheidi

This figure shows the co-authorship network connecting the top 25 collaborators of Meteb Al‐Foheidi. A scholar is included among the top collaborators of Meteb Al‐Foheidi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meteb Al‐Foheidi. Meteb Al‐Foheidi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Khan, Mansoor Ahmed, Mohammed Alharbi, Mohammed Aseeri, et al.. (2025). Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system. Expert Review of Clinical Pharmacology. 18(6). 323–331.
2.
3.
Alhifany, Abdullah A., et al.. (2024). Assessment of Cardiotoxicity Incidence in Patients Receiving HER-2-Targeted Therapies for Breast Cancer in Saudi Arabia. Clinical Medicine Insights Oncology. 18. 1383418841–1383418841. 1 indexed citations
4.
5.
6.
Rae, William, et al.. (2020). Is mammographic density a marker of breast cancer phenotypes?. Cancer Causes & Control. 31(8). 749–765. 5 indexed citations
7.
8.
Zekri, Jamal, et al.. (2020). Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria. Breast Care. 15(6). 642–647. 2 indexed citations
9.
Al‐Μansour, Mubarak, Meteb Al‐Foheidi, & Ezzeldin M. Ibrahim. (2020). Efficacy and safety of second‑generation CAR T‑cell therapy in diffuse large B‑cell lymphoma: A meta‑analysis. Molecular and Clinical Oncology. 13(4). 33–33. 25 indexed citations
10.
Alsaleh, Khalid, et al.. (2020). Prediction of response to neoadjuvant hormonal therapy (NAHT) using upfront oncotype Dx recurrence score (RS): Results from the SAFIA phase III trial.. Journal of Clinical Oncology. 38(15_suppl). 594–594. 4 indexed citations
11.
Al‐Foheidi, Meteb, et al.. (2019). Granulocyte Colony Stimulating Factor (G-CSF) Induced Splenic Infarction in Breast Cancer Patient Treated with Dose-Dense Chemotherapy Regimen. SHILAP Revista de lepidopterología. 2019. 1–4. 5 indexed citations
12.
13.
Trifirò, Gianluca, Meteb Al‐Foheidi, Ahmed Al‐Jedai, et al.. (2018). First GCC stakeholder meeting on approval process, interchangeability/substitution and safety of biosimilars 2017 – Report. Generics and Biosimilars Initiative Journal. 7(4). 158–163. 1 indexed citations
14.
Al‐Μansour, Mubarak, et al.. (2017). Hodgkin Lymphoma Outcome: A Retrospective Study from 3 Tertiary Centers in Saudi Arabia. Oncology Research and Treatment. 40(5). 288–292. 13 indexed citations
15.
Zekri, Jamal, et al.. (2015). LAPATINIB-BASED THERAPY FOR WOMEN WITH ADVANCED/ METASTATIC HER2 POSITIVE BREAST CANCER. Experimental Oncology. 37(2). 146–150. 3 indexed citations
16.
Ibrahim, Ezzeldin M., Meteb Al‐Foheidi, Mubarak Al‐Μansour, Ghieth A. Kazkaz, & Tahir Yunus. (2014). The Prognostic and Predicting Roles of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Meta-Analysis. 6(1). 9–19. 3 indexed citations
17.
Al‐Foheidi, Meteb, Mubarak Al‐Μansour, & Ezzeldin M. Ibrahim. (2013). Breast cancer screening: review of benefits and harms, and recommendations for developing and low-income countries. Medical Oncology. 30(2). 471–471. 43 indexed citations
18.
Ibrahim, Ezzeldin M., et al.. (2012). Increased Risk of Second Lung Cancer in Hodgkin’s Lymphoma Survivors: A Meta-analysis. Lung. 191(1). 117–134. 27 indexed citations
19.
Ibrahim, Ezzeldin M., et al.. (2012). Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a meta-analysis. BMC Cancer. 12(1). 197–197. 49 indexed citations
20.
Chia, Stephen, et al.. (2010). 217 Outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma: a population based study from British Columbia. European Journal of Cancer Supplements. 8(3). 122–122.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tobias Engler Breakdown of academic impact, for papers by Akira Yabuno Breakdown of academic impact, for papers by Joan Tymon‐Rosario Breakdown of academic impact, for papers by Luca Seriau Breakdown of academic impact, for papers by Britt B.M. Suelmann Breakdown of academic impact, for papers by Hilary Stobart Breakdown of academic impact, for papers by Amandeep Godara Breakdown of academic impact, for papers by Caigang Xu Breakdown of academic impact, for papers by Shu-Lian Wang Breakdown of academic impact, for papers by Constanze Elfgen
Rankless by CCL
2026